Developing hormone receptor-based medicines, for lif
A clinical trial evaluating an oral medicine to potentially treat stress urinary incontinence (SUI)
Our lead product candidate is focused on stress urinary incontinence, which affects up to 35 percent of adult women. Learn about our pipeline »
May 18, 2018
GTx Updates Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at 2018 AUA Annual Meeting MORE »May 15, 2018
GTx Provides Corporate Update and Reports First Quarter 2018 Financial Results MORE »Key Opinion Leader (KOL) Luncheon
09/28/17 12:00 p.m. ETWebcast Presentation »
Key Opinion Leader (KOL) Luncheon Presentation [PDF] »